Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study using botulinum toxin type A as headache prophylaxis for migraine patients with frequent headaches

Next Previous
Trial Profile

A study using botulinum toxin type A as headache prophylaxis for migraine patients with frequent headaches

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms PREEMPT-2
  • Sponsors AbbVie; Allergan

    • Most Recent Events

    • 01 Jan 2023 Results assessing relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine de-novo indirect treatment comparisons (ITCs) based on results from NCT02066415, PREEMPT 1 & PREEMPT 2,published in the Current Medical Research and Opinion.
    • 29 Oct 2021 According to an AbbVie media release, results of post-hoc analysis from two trials (PREEMPT-1 and PREEMPT-2) were presented at the International Headache Congress (IHC) 2021.
    • 08 Sep 2021 According to an AbbVie media release, data from a post-hoc analysis of the Phase 3 PREEMPT trials will be presented at the International Headache Congress 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top